Finepoint Capital LP Buys New Shares in Xencor, Inc. (NASDAQ:XNCR)

Finepoint Capital LP bought a new stake in Xencor, Inc. (NASDAQ:XNCR) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 660,000 shares of the biopharmaceutical company’s stock, valued at approximately $15,167,000. Xencor accounts for approximately 0.9% of Finepoint Capital LP’s holdings, making the stock its 11th largest position.

A number of other institutional investors have also added to or reduced their stakes in XNCR. Vanguard Group Inc. lifted its holdings in shares of Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after acquiring an additional 418,040 shares during the period. Geode Capital Management LLC lifted its holdings in Xencor by 12.3% during the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company’s stock valued at $37,578,000 after purchasing an additional 179,526 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in Xencor by 21.3% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company’s stock valued at $25,102,000 after buying an additional 192,080 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Xencor by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 630,640 shares of the biopharmaceutical company’s stock worth $14,492,000 after buying an additional 3,652 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Xencor by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 437,152 shares of the biopharmaceutical company’s stock valued at $10,046,000 after acquiring an additional 18,586 shares during the last quarter.

Analysts Set New Price Targets

XNCR has been the topic of a number of research analyst reports. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Trading Down 2.6 %

Shares of NASDAQ:XNCR opened at $8.69 on Friday. The company’s fifty day simple moving average is $14.51 and its 200 day simple moving average is $19.69. The firm has a market cap of $612.31 million, a price-to-earnings ratio of -2.72 and a beta of 0.90. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12 month low of $8.45 and a 12 month high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. As a group, research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.